Objective:

The article examines WHO guidance on obesity treatment for children and adolescents and discusses evidence gaps in lifestyle and pharmacological approaches.

Approach:

• Guidelines: Issued on 7 October 2026, the WHO guidelines advise against pharmacological treatment, including GLP-1 receptor agonists (GLP-1RAs), for children younger than 10. For adolescents aged 10–19, medication is recommended only after alternative treatment options have been exhausted.
• Evidence: The article describes evidence for pharmacotherapy as low quality and evidence for conventional weight-loss approaches, including diet and exercise, as very low quality.
• Context: It discusses social and environmental influences on youth obesity and research needs concerning lifestyle interventions, medication safety, long-term treatment, and potential misuse.

Key Findings:

• The proportion of adolescents worldwide who were overweight rose from 8% in 1990 to 20% in 2024.
• About 70% of adolescents with obesity remain affected at age 30. Youth obesity is associated with long-term conditions including chronic kidney disease and type 2 diabetes, as well as immediate risks including poor oral health, asthma, hypertension, stigma, depression, and lower educational attainment.
• Access to safe places for exercise and affordable nutritious food can constrain lifestyle interventions; children often have limited control over their diets.
• Evidence on GLP-1RA use in adolescents is sparse. The article calls for extended follow-up to assess safety during development and puberty.
• Adult evidence indicates weight regain after GLP-1RA discontinuation, raising questions about long-term treatment and support for people who stop medication.
• The article identifies potential concerns about unsupervised access, misuse, and effects on eating disorders and body dysmorphia.

Interpretation:

The article describes how social and environmental factors shape young people’s choices and highlights evidence gaps in lifestyle and pharmacological treatment.

Limitations:

• The article notes that benefits of food-voucher initiatives have not been examined in children.
• Evidence on GLP-1RA efficacy and safety in adolescents is described as sparse, with long-term developmental effects unresolved.

Conclusion:

The article calls for treatment options grounded in evidence and responsive to the complex environments in which children and adolescents live.

Sources:

• Young people with obesity deserve better care